Page 328 - ATP-P 11th Ed

° Generalized anxiety disorder
° Psychosis
° Schizophrenia or other major psychiatric disorders
° History of convulsions
Pregnancy Category C
Side-effects:
• Cardiac rhythm disturbances
• Exercise caution when performing activities requiring alertness and fine motor coordi-
nation such as driving, piloting, operating heavy machinery as dizziness, loss of balance
have occurred with mefloquine during and following its use.
Adverse reactions:
• Reactions (symptoms) attributable to mefloquine cannot be distinguished from symp-
toms of malaria. Due to long half-life of the drug, symptoms could persist for several
weeks following the last dose.
• Prophylaxis
SECTION 3 ° ° ° Dizziness
Vomiting (3%)
Syncope (fainting)
Extrasystoles (skipped heartbeats; <1%)
°
• Treatment
° Dizziness, headache
° Myalgia (muscle aches)
° Nausea, vomiting
° Fever, chills
° Diarrhea
° Skin rash
° Abdominal pain
° Fatigue
° Loss of appetite
° Tinnitus (ringing in the ears)
Other notes:
• Patients given mefloquine for P. vivax are at high risk for relapse and should subse-
quently receive primaquine.
• There is insufficient clinical data to document mefloquine’s effect on malaria caused by
P. ovale or P. malariae.
• Liver impairment can prolong the elimination of mefloquine.
• When mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of
immunization cannot be excluded. Therefore, complete attenuated oral live vaccinations
at least 3 days before starting mefloquine.

318 SECTION 3 RECOMMENDED DRUG LIST (RDL)